{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["brigatinib"]],"indication":"ALK-rearranged non-small-cell lung cancer","name":"NCT01449461","nct_id":"NCT01449461","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01449461. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Brigatinib 30 mg/60 mg, tablets, orally, once daily (QD) in each cycle of 28 days (Approximately up to 7.3 years).","label":"Brigatinib 30 mg QD/60 mg QD","type":"EXPERIMENTAL"},{"description":"Brigatinib 90 mg, tablets, orally, QD in each cycle of 28 days (Approximately up to 7.3 years).","label":"Brigatinib 90 mg QD","type":"EXPERIMENTAL"},{"description":"Brigatinib 120 mg, once daily or 60 mg, twice daily (BID), tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).","label":"Brigatinib 120 mg QD/60 mg BID","type":"EXPERIMENTAL"},{"description":"Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days.","label":"Brigatinib 90 mg QD-180 mg QD","type":"EXPERIMENTAL"},{"description":"Brigatinib 180 mg, once daily or 90 mg, BID, tablets, orally in each cycle of 28 days (Approximately up to 7.3 years).","label":"Brigatinib 180 mg QD/90 mg BID","type":"EXPERIMENTAL"},{"description":"Brigatinib 240 mg, QD or 120 mg, BID or 300 mg once daily, tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).","label":"Brigatinib 240 mg QD/120 mg BID/300 mg QD","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2020-02-18","type":"ACTUAL"},"conditions":["Lymphoma, Large-Cell, Anaplastic","Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":137,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Brigatinib","otherNames":["ALUNBRIG™","AP26113"],"type":"DRUG"}],"last_update":"2021-08-17","lead_sponsor":"Ariad Pharmaceuticals","official_title":"A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2015-11-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recommended Phase 2 Dose (RP2D) of Brigatinib","timeFrame":"28 days"},{"measure":"Objective Response Rate (ORR)","timeFrame":"From Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years)"}],"references":[{"citation":"Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. 2018 Sep 10;36(26):2693-2701. doi: 10.1200/JCO.2017.77.5841. Epub 2018 May 16.","pmid":"29768119","type":"DERIVED"},{"citation":"Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.","pmid":"27836716","type":"DERIVED"},{"citation":"Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw. 2013 Feb 1;11(2):161-9. doi: 10.6004/jnccn.2013.0024.","pmid":"23411383","type":"DERIVED"}],"start_date":{"date":"2011-09-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)","url":"https://clinicaltrials.gov/study/NCT01449461"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01449461"}